

Friday, 14 November 2025

08:00 - 08:15	Welcome & Introduction Chairs: Corey Cutler (US) & Anna Sureda (ES)	
08:15 - 09:00	Keynote Lecture I: Relapse landscape and mechanism early and late Chairs: Corey Cutler (US) & Anna Sureda (ES) Probing leukaemia-host co-evolution in relationship to response and resistance to allo-HSCT	Catherine J. Wu (US)
09:00 - 10:15	Session I: Relapse after Allo Chairs: Victoria Potter (UK) & Luca Vago (IT)	
09:00 - 09:15	T-cell immunology predicting relapse post-allogeneic stem cell transplant	Mahasweta Gooptu (US)
09:15 - 09:30	Immunological prevention of relapse	Pramila Krishnamurthy (UK)
09:30 - 09:45	Personalised / Precision approaches to target immune escape after allogeneic stem cell transplant	Luca Vago (IT)
09:45 - 09:55	<i>Case Presentation:</i> Mutation clearance predicts relapse in accelerated-phase myelofibrosis after transplantation	Nicolaus Kröger (DE)
09:55 - 10:05	<i>Case Presentation:</i> A Phase I Dose Escalation and Expansion Trial of Lyt-200 (a First-In-Class Anti-Galectin-9 Antibody) Alone and in Combination with Venetoclax/HMA in R/R AML/MDS	Aleksandra Filipovic (US)
10:05 - 10:15	<i>Case Presentation:</i> Treatment of MDS relapse after allogeneic stem cell transplantation (alloSCT): Significantly reduced relapse incidence after donor change for the second alloSCT	Giuliano Filippini (DE)
10:15 - 10:25	<i>Case Presentation:</i> Single-cell transcriptomics reveals early dynamic immune trajectories associated with clinical outcome following allogeneic stem cell transplantation	Kriti Verma (UK)
10:25 - 10:30	Panel discussion	
10:30 - 11:00	Coffee Break	
10:45 - 12:00	Session II: Mechanisms of Relapse after auto-HCT in MM and Lymphoma Chair: Anna Sureda (ES)	
11:00 - 11:20	Relapse Mechanisms after Immunotherapy in MM	Alison Moskowitz (US)
11:20 - 11:40	Checkpoint inhibitors in Hodgkin's Lymphoma	
11:40 - 12:00	Panel discussion	
12:00 - 13:00	Lunch Break	

13:00 - 14:15

Session III: Relapse after CAR**Chair:** Nirali N. Shah (US)**Biology of antigen escape**

13:00 - 13:15

Biology of antigen escape

Kara Davis (US)

13:15 - 13:20

Case presentation: Treatment of antigen escape, including lineage switch

Sara Ghorashian (UK)

13:20 - 13:40

Panel discussion

Advances in combinatorial antigen targeting strategies

13:40 - 13:55

Advances in combinatorial antigen targeting strategies

Christian Seitz (DE)

13:55 - 14:00

Case Presentation:

Development of a CAR-NK Therapy Regulated by the KLRC1 Locus as a New Platform for More Selective Control of Acute Myeloid Leukemia

Asunción Borrego (US)

14:00 - 14:15

Panel discussion

14:15 - 14:45

Coffee Break

14:45 - 16:00

Best Abstracts Session**Chairs:** Michael Bishop (US) & Alan Wayne (US)

14:45 - 14:55

Case Presentation:

Exploiting transcriptional and metabolic vulnerabilities to counteract leukemia immune escape after transplantation

Annalisa Tameni (IT)

14:55 - 15:05

Case Presentation:

Base-editing Human Hematopoietic Stem Cells to Enable Venetoclax Post-Transplant Maintenance Therapy for AML

Joanne Baek (US)

15:05 - 15:15

Case Presentation:

Defining the cellular and molecular architecture of human bone marrow in myelodysplastic syndromes

Susan DeWolf (US)

15:15 - 15:25

Case Presentation:

Phenotypes and TCR repertoires of leukaemia cutis-associated T cells

Livius Penter (DE)

15:25 - 15:35

Case Presentation:

Trials in Progress: A Phase1/2 Study Evaluating the Efficacy and Safety of T-Cell Receptor Engineered Donor T Cells in Subjects with Acute Myeloid Leukemia, Myelodysplastic Syndromes, or Acute Lymphoblastic Leukemia Who Are Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

Chrystal Louis (US)

15:35 - 15:45

Case Presentation:

Real-world outcomes of adult B-ALL patients who experience relapsed or refractory disease following brexucabtagene autoleucel

Gregory Roloff (US)

15:45 - 16:00

Q&A

16:00 - 17:30

Welcome Reception + Poster Session

Saturday, 15 November 2025

08:00 - 08:45	Keynote Lecture III: Relapse after CAR T Chair: Nicolaus Kröger (DE) Relapse after CAR T	Saar Gill (US)
08:45 - 10:00	Session IV: MRD/new technologies for monitoring MRD (CTDNA) Chair: Chris Hourigan (US)	
08:45 - 09:05	Peripheral Residual Disease Monitoring using Mass Spectrometry and Next-Gen Methods in Transplant-Eligible Patients with Multiple Myeloma	Bruno Paiva (ES)
09:05 - 09:25	Computational and immune-integrative approaches to optimise MRD detection after allogeneic transplant	Sylvie Freeman (UK)
09:25 - 09:45	Pre and Post transplant NGS-MRD in patients allografted for acute leukaemia	Lori Muffly (US)
09:45 - 10:00	Panel discussion	
10:00 - 10:30	Coffee Break	
10:30 - 11:45	Session V (part I): Preventing Relapse in Patients Allografted for AML Chairs: Charles Craddock (UK) & Sergio Giralt (US)	
10:30 - 10:45	Current / Future Trials of the BMT CTN Group Aimed at Preventing Relapse	Yi-Bin Chen (US)
10:45 - 11:00	Current / Future Trials of the UK IMPACT Group Aimed at Preventing Relapse	Victoria Potter (UK)
11:00 - 11:15	Current / Future Trials of the German Transplant Group Aimed at Preventing Relapse	Thomas Schroeder (DE)
11:15 - 11:45	Panel discussion	
11:45 - 12:00	Break	
12:00 - 13:00	Session V (part II): Preventing Relapse after CAR-T cell Therapy Chairs: Charles Craddock (UK) & Victoria Potter (UK)	
12:00 - 12:10	Optimising pre-infusion strategies	Michael Jain (US)
12:10 - 12:20	How to modify the cellular inoculum to increase persistence	Claire Roddie (UK)
12:20 - 12:30	Post-infusion interventions	Rebecca Gardner (US)
12:30 - 13:00	Discussion	
13:00 - 14:00	Lunch Break	
14:00 - 15:00	Session VI: Microbiome, tumour immunology and relapse Chair: Mette Hazenberg (NL)	
14:00 - 14:15	Long-distance microbial mechanisms impacting cancer immunosurveillance	Camille Bigenwald (FR)
14:15 - 14:30	Intestinal microbiota, cellular therapy and relapse: mechanisms and implications	Melody Smith (US)
14:30 - 14:45	Approaches to protect the microbiome from damage and its association with relapse	Hendrik Poeck (DE)
14:45 - 15:00	Panel discussion	

ASTCT + EBMT

7TH INTERNATIONAL

RELAPSE

After Transplant and Cellular Therapy (HSCT²)

CONFERENCE

ASTCT[®]
American Society for
Transplantation and Cellular Therapy

EBMT

14-15 November 2025

Madrid, Spain

20
25

15:00 - 16:05

Session VII: Maintenance post Cell Therapy

Chair: Saar Gill (US)

15:00 - 15:15

Post-transplant TCR engineered T cells to maintain remission and prevent relapse

15:15 - 15:30

DLI for prevention of relapse post alloSCT

15:30 - 15:45

Post-transplant maintenance with FLT3 inhibitors; all the news that's fit / not fit to print

15:45 - 16:05

Panel discussion

Marie Bleakley (US)

Christoph Schmid (DE)

Mark Levis (US)

16:05 - 16:30

Concluding Remarks

Alan Wayne (US), Nicolaus Kröger (DE) & Michael Bishop (US)